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Summary
 
Reactivation from latent cytomegalovirus (CMV) infection is often associated with conditions
of immunosuppression and can result in fatal disease. Whether the maintenance of systemic
CMV latency is mainly governed by factors of the infected cell or by immune control functions
is unknown. Likewise, the putative immune control mechanisms which could prevent the in-
duction and spread of recurrent CMV infection are not clearly identified. We took advantage
of latently infected B cell–deficient mice and a sensitive method for virus detection to study
CMV reactivation after ablation of lymphocyte subsets. A crucial role of both T lymphocytes
and natural killer (NK) cells was demonstrated. Within 5 d after depletion of lymphocytes, pro-
ductive infection occurred in 50% of mice, and 14 d later 100% of mice exhibited recurrent in-
fection. A hierarchy of immune control functions of CD8
 
1
 
, NK, and CD4
 
1
 
 cells was estab-
lished. Reactivation was rare if only one of the lymphocyte subsets was depleted, but was
evident after removal of a further subset, indicating a functional redundancy of control mecha-
nisms. The salivary glands were identified as the site of most rapid virus shedding, followed by
the detection of recurrent virus in the lungs, and eventually in the spleen. Our findings docu-
ment a previously unknown propensity of latent CMV genomes to enter productive infection
immediately and with a high frequency after immune cell depletion. The data indicate that
only the sustained cellular immune control prevents CMV replication and restricts the viral ge-
nome to a systemic state of latency.
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A
 
fter primary CMV infection, immune control mecha-
nisms effectively prevent overt disease and terminate
virus replication. However, ultimate clearance of the viral
genome is not achieved. Instead, CMVs are able to remain
lifelong at specific sites in their natural hosts. During the
nonproductive, latent state of infection, the viral gene ex-
pression is minimized to a small subset of genes (1, 2).
From latent infection the viral replication cycle can be ini-
tiated and results in transient phases of virus shedding and
recrudescent disease. The establishment of latency and the
reactivation to episodes of recurrent infection are general
hallmarks of herpesvirus biology.
The lifelong persistence of the herpesvirus genome ren-
ders the host at permanent risk for recurrent infection. In
immunocompromised patients like transplant recipients or
individuals with impaired immunity due to infection with
HIV, recurrence of human CMV (HCMV)
 
1
 
 infection fre-
quently leads to overt manifestations of disease (3). Al-
though impairment of cellular immune control functions is
a prime risk factor for CMV recurrence, it is apparent that
only some patients at risk develop CMV disease. The iden-
tification of predisposing factors is clearly needed to predict
the incidence and outcome of reactivation events.
The risk factors for virus reactivation and development
of recurrent disease are poorly characterized, but are
 
1
 
 
 
Abbreviations used in this paper:
 
 HCMV, human cytomegalovirus; HSV,
herpes simplex virus; MCMV, murine cytomegalovirus; MEF, mouse
embryo fibroblast(s); p.i., postinfection; SGV, salivary gland virus.
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known to include at least three factors. First is a high load
of latent genomes, since the frequency of initiation of
the virus replication program increases with the number of
latently infected cells (4, 5). Second, stimulation of he-
matopoietic cells can initiate reactivation by switching the
transcriptional control to productive infection (6). Third,
immune control must fail to attack virus-infected cells dur-
ing or shortly after initiation of the replicative program.
From clinical experience with immunocompromised pa-
tients it is clear that clinical reactivation of certain herpesvi-
ruses, namely CMV, is more frequent and clinically rele-
vant than others. Two explanations are possible. Either the
unknown frequency of reactivation at the cellular level is as
low as for other herpesviruses but manifest recurrence is
high due to immunoevasive gene functions of CMV (7),
or, alternatively, despite the subversive gene functions, the
frequency of reactivation events is in fact very high but dis-
guised by a stringent and continuous immune control.
To distinguish between these possibilities, we have es-
tablished the model of latent murine CMV (MCMV) in-
fection in the Ig 
 
m
 
 chain–deficient mouse (8). Previous
studies in these mice devoid of B cells and antibodies re-
vealed that antibodies are not required for the resolution of
primary CMV infection, and latency is established with the
same kinetics as in seropositive controls. The load of viral
genomes that represents an independent risk factor for the
occurrence of recurrent infection (5) is identical between B
cell–deficient and normal mice (8). Taking advantage of
the facilitated detection of recurrent CMV in B cell–defi-
cient mice and by using an optimized assay for the detec-
tion of infectious virus in organs, we were able to study the
contribution of lymphocyte subsets to the prevention and
immune surveillance of recurrent CMV infection. The data
indicate that the removal of T lymphocytes and NK cells
rapidly results in CMV recurrence at multiple sites. Thus,
the clinical state of CMV latency is governed by immune
control functions.
 
Materials and Methods
 
Establishment of Latency in B Cell–deficient Mice.
 
Mice homozy-
gous for a 
 
m
 
 chain mutation (
 
m
 
MT/
 
m
 
MT; reference 9) were bred
in the Central Animal Facility, Rijeka University School of Med-
icine. Homozygous and heterozygous offspring were distin-
guished by testing their sera for the presence of IgM antibodies.
The absence of CD45R(B220)
 
1
 
 and IgM
 
1
 
 cells in the spleens of
homozygous animals was verified by cytofluorometry in B cell–
deficient animals. 6–8-wk-old mice were injected in the rear
footpad with 10
 
5
 
 PFU of tissue culture–derived virus in a volume
of 50 
 
m
 
l. Latency was established within 12 wk after primary in-
fection as determined by monitoring infectious virus in tissues.
 
Viruses.
 
The Smith strain of MCMV (VR-194; American
Type Culture Collection, Rockville, MD) was propagated in
mouse embryo fibroblasts (MEFs) and concentrated by ultracen-
trifugation on a 15% sucrose gradient (10). The salivary gland iso-
late of MCMV (SGV) was propagated in 6 Gy 
 
g
 
-irradiated
MCMV-infected mice of the BALB/c strain. 2 wk after infec-
tion, salivary glands were collected, homogenized, and stored at
 
2
 
70
 
8
 
C.
 
Plaque Assay for the Detection of Infectious MCMV in Tissues.
 
Mouse organs were frozen immediately at 
 
2
 
70
 
8
 
C after collec-
tion. The presence of infectious virus was determined by titrating
organ homogenates using a standard plaque assay (10). The detec-
tion limit of the assay was extended to 1 PFU per organ homoge-
nate as described previously (8). In brief, each organ was homog-
enized in 10 ml of MEM supplemented with 5% FCS and
distributed after log
 
10
 
 titration in 24-well plates containing a
semiconfluent monolayer of MEFs (10
 
5
 
 cells/well). After 30 min
of incubation at 37
 
8
 
C, plates were centrifuged at 1,100 
 
g
 
 for 30
min. Plaques were counted 7 d later.
 
In Vivo Assay for the Detection of Infectious MCMV in Tissues.
 
The presence of infectious virus in organs and blood of latently
infected B cell–deficient mice was tested by using a sensitive in
vivo assay. 0.5 ml of blood or homogenized organs was resus-
pended in 2 ml of MEM supplemented with 3% FCS. One half
of each homogenate was diluted 1:10 and tested for the presence
of virus. The other half of the homogenate was injected intraperi-
toneally into a 6–8-wk-old naive C57BL/6 mouse. To exclude
the possibility of virus reactivation in living cells, collected organs
(salivary glands, lungs, and spleen) and peripheral blood speci-
mens were freeze-thawed before homogenization. Indicator mice
were kept in separate cages to prevent horizontal transmission of
MCMV. Sera were collected 4 wk after the injection and tested
for the presence of MCMV-specific antibodies by ELISA (11).
Mice were subsequently immunodepleted by a single injection of
cyclophosphamide (EndoxanR, 150 mg/kg) and a cocktail of cy-
tolytic mAbs (1 mg/animal) to CD4 (YTS 191.1.2.; reference
12), CD8 (YTS 169.4.2; reference 12), and NK1.1. (PK 136; ref-
erence 13). mAb treatment was repeated after 1 wk. In addition,
the animals were injected with hydrocortisone sodium succinate
(125 mg/kg) every other day. Virus titers in salivary glands were
determined 2 wk after initiating immunodepletion. To determine
the sensitivity of the assay, organ homogenates of naive B cell–
deficient mice were mixed with ascending doses (0.2, 2, and 20
PFU; titer based on the centrifugal enhancement of infectivity) of
SGV and subjected to the same protocol. In contrast to organ ho-
mogenates from latently infected mice, injection of salivary gland
or lung homogenates from uninfected animals supplemented with
2 or 0.2 PFU of infectious virus led to seroconversion in 100 and
20%, respectively, of mice, and infectious virus could be recov-
ered from 100 and 20%, respectively, of recipients after immu-
nodepletion (data not shown).
 
Depletion of Lymphocyte Subsets.
 
Lymphocyte subsets in la-
tently infected mice were selectively depleted 12 wk postinfec-
tion (p.i.) as described previously (11, 14). In brief, 500 
 
m
 
g of pu-
rified mAbs was used for the elimination of the CD4
 
1
 
, CD8
 
1
 
,
and NK1.1
 
1
 
 cell subsets. Mice were injected every fifth day
throughout the duration of the experiment. The efficacy of the
depletion of cells was monitored by standard two-color cytofluo-
rometric analysis of spleen and lymph node cells using the follow-
ing reagents: anti-Lyt 2–FITC (Becton Dickinson, San Jose, CA),
anti–L3T4-PE (Becton Dickinson), anti–NK1.1-biotin (Phar-
Mingen, San Diego, CA), anti–CD2-PE (PharMingen), and strep-
tavidin-FITC (Becton Dickinson). NK cells were analyzed on the
gated CD2
 
1
 
 population indicating efficacious depletion of NK1.1
 
1
 
cells in mice treated with PK 136 mAb. In addition, functional
depletion of NK cells in infected B cell–deficient mice was con-
firmed by standard chromium-release assays against YAC-1 target
cells.
 
In Vivo Neutralization of IFN-
 
g
 
.
 
Neutralization of IFN-
 
g
 
 was
performed by injection of purified mAb R4.6A2 (15) or a poly-
clonal rabbit anti–rIFN-
 
g
 
 antiserum described previously (16).
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Mice were injected intraperitoneally with 200 
 
m
 
g of mAb or 250
 
m
 
l of rabbit antiserum at the beginning of the experiment and ev-
ery other day thereafter. The neutralization capacity of the rabbit
antiserum was determined by an in vitro assay based on the ability
of rIFN-
 
g
 
 to induce MHC class I molecule expression on MEFs
(0.02 ng of rIFN-
 
g
 
 [1 U] induced maximal expression of L
 
d
 
 mol-
ecules on fibroblasts after 48 h of incubation). rIFN-
 
g
 
 was neu-
tralized with serial dilutions of antiserum at 4
 
8
 
C for 2 h, and 1 ml of
each sample was then added to a semiconfluent culture of MEFs
(10
 
5
 
 cells/well, 24-well plates). Expression of L
 
d
 
 molecules was
measured after 48 h of incubation by flow cytometry using anti-
L
 
d
 
 biotin–conjugated antibodies (PharMingen) and streptavidin-
FITC as a second reagent (Becton Dickinson). The neutralizing
capacity of the antiserum was defined as the reciprocal value of
the highest serum dilution that reduced MHC I expression by
50% compared with cultures treated with IFN-
 
g
 
. According to
this assay, 1 ml of anti–IFN-
 
g
 
 serum was able to neutralize 
 
z
 
0.8
 
m
 
g of rIFN-
 
g
 
.
 
Statistical Analysis and Deduction of a Mathematical Model of Reac-
tivation.
 
The percentage of mice in which recurrent virus was
detected was used to generate a mathematical model describing
the probability of recurrent infection over time. The following
assumptions were made: (
 
a
 
) a single reactivation event will lead to
the generation of at least one infectious virion; (
 
b
 
) reactivation is a
stochastic process; and (
 
c
 
) at least 24 h are required from activa-
tion of the viral genome to the production of infectious virus.
The probability of recurrence is described by the Poisson distri-
bution (valid for time 
 
t
 
 
 
.
 
 
 
t
 
0
 
):
where 
 
t
 
 is time, 
 
t
 
0
 
 is the time at which the first progeny virions
can be detected after immunodepletion, and 
 
T
 
0
 
 is the time period
(starting from 
 
t
 
0
 
) in which recurrent virus can be detected in
100% of mice. A linear function (see 
 
broken line
 
, Fig. 1 
 
B
 
) is ap-
proximated from the Poisson distribution as curve P(
 
t
 
) 
 
5
 
 (
 
t
 
 
 
2
 
 
 
t
 
0
 
)/
 
T
 
0
 
 for (
 
t
 
 
 
2
 
 
 
t
 
0
 
)/
 
T
 
0
 
 
 
,
 
 0.5.
 
Results
 
Rapid CMV Recurrence after Depletion of T Lymphocytes and
NK Cells in Latently Infected B Cell–deficient Mice.
 
m
 
MT/
 
m
 
MT mice lacking B cells and antibodies terminate acute
MCMV infection and establish and maintain latency as
quickly and efficiently as their heterozygous littermates.
However, during CMV recurrence, the virus titer is in-
creased in organs 100–1,000-fold in the absence of virus-
specific antibodies compared with normal littermates (8).
Therefore, in normal mice the sensitive detection of reacti-
vation events is impeded by the neutralization of virus by
antibodies. To determine the frequency of reactivation and
the sites and kinetics of recurrent CMV infection, we used
latently infected 
 
m
 
MT/
 
m
 
MT mice and depleted the major
lymphocyte subsets. Mice were depleted simultaneously of
CD4
 
1
 
, CD8
 
1
 
, and NK1.1
 
1
 
 cells by treatment with cy-
tolytic mAbs and killed at various time points after treat-
ment. Already 3 d after immunodepletion, in two out of
nine (22%) mice, recurrent virus could be detected in the
salivary glands. 5 and 7 d after treatment, respectively, virus
titers were detected in 2 out of 8 (25%) in the lungs and in
2 out of 12 (17%) in the spleen, respectively (Fig. 1 
 
A
 
).
P t( ) 1 exp t t0–( )– ] T0⁄[–=
Within 2 wk after the initiation of immunodepletion, re-
currence occurred in the salivary glands and lungs of all
mice. In contrast, in seropositive control mice receiving the
same cocktail of mAbs, recurrent MCMV was seen only
occasionally and in very low titers in the salivary glands and
in the lungs of very few mice on day 14 (Fig. 1 A).
Fig. 1 B depicts this observation as the percentage of
mice in which CMV reactivation occurred in the salivary
glands as a function of time. Based on this curve, we can
deduce two biological parameters of CMV reactivation at
this site: t0, the time point at which infectious virus is man-
ifest for the first time, and T0, the time period required for
the occurrence of reactivation in the entire population of
mice (see Materials and Methods). By extrapolating the lin-
ear portion of the Poisson distribution (broken line), it is
possible to determine the time in which recurrent virus is
detected in 100% of mice. Based on this mathematical
model, we determine (a) that z1.5 d (t0) after immunode-
pletion, the first progeny virus is detectable in the salivary
glands; (b) that the average time required to detect recur-
rent virus at this site in 50% of the animals (recurrence
event, RE50) is ,6 d; and (c) that all mice develop recur-
rent CMV infection in the salivary glands within 8 d (T0).
Figure 1. MCMV recurrence
after depletion of T lympho-
cytes and NK cells. (A) Latently
infected mMT/mMT B cell–defi-
cient mice and heterozygous
mMT/1 mice were immunode-
pleted of CD41, CD81, and
NK1.11 cells 12 wk p.i. Infec-
tious virus in the salivary glands,
lungs, and spleen was determined
after immunodepletion as indi-
cated. Shown are the titers of re-
current virus in the salivary
glands (top), lungs (middle), and
spleen (bottom) of homozygous
(d) and heterozygous (s) mice.
DL, Detection limit. (B) The
percentage of mice in which re-
current virus was detected in the
salivary glands (solid line) was
used to generate a mathematical
model describing the probability
of recurrence over time (see Ma-
terials and Methods). Broken line,
A linear function differentiated
from the Poisson distribution as a
curve P(t) 5 (t 2 t0)/T0, for (t 2
t0)/T0 , 0.5. Arrow, The time
point at which recurrent virus is
predicted in 100% of mice.
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With a delayed but similar kinetics, recurrent virus was also
detected in the lungs and finally in the spleen (see Fig. 1 A).
From these data, we conclude that in the absence of T
lymphocytes and NK cells the emergence of recurrent
CMV is a rapid process.
CMV Recurrence in B Cell–deficient Mice Is Stochastic and
Multifocal. The emergence of recurrent virus in the sali-
vary glands and the delayed increase of infectious virus in
the lungs and spleens of B cell–deficient mice, albeit at a
lower titer, could be explained by two possibilities. First,
recurrence could be a stochastic event that occurs coinci-
dentally but independently in different tissues. Alterna-
tively, and specifically in the antibody-deficient environ-
ment of our experimental setting, recurrent virus could
originate from a single organ, e.g., the salivary glands, and
subsequently disseminate to the other organs tested. To ad-
dress this question, we compared titers of recurrent virus in
different organs of individual mMT/mMT mice. At day 7
after ablation, discrete patterns with cases of positive lungs
corresponding to negative salivary glands and vice versa
were observed (data not shown). 1 wk later, individual mice
exhibited widely different titers of recurrent virus in the sal-
ivary glands versus the lungs and spleen, without correlation
to the productive infection between these organs (Table 1).
In addition, selective reactivation restricted to a single organ
or infectious virus present in the salivary glands and the
lungs, but not in the spleen, was also seen under different
experimental conditions (Table 2, and Fig. 2). Altogether,
the results exclude that multifocal detection of recurrent
MCMV requires dissemination of virus from the salivary
glands to multiple peripheral sites. In agreement with previ-
ous reports, the data support the notion that recurrence oc-
curs as a stochastic event independently at multiple sites (5).
The Presence of Cell-mediated Immunity Prevents the Forma-
tion of Recurrent CMV. Hypothetically, the virus recov-
ered after immunodepletion could represent the expansion
of infectious virus that preexisted at very low levels rather
than reactivation from true latency. To test this possibility,
an in vivo assay detecting infectivity with very high sensi-
tivity was developed, allowing the detection of single in-
fectious particles within an organ (see Materials and Meth-
ods). All organs from all latently infected mice analyzed
remained negative for infectious virus (data not shown).
These results strongly argue against a general persistence
of infectious virus at low levels, and confirm again the
existence of a nonproductive state of infection in B cell–
deficient mice. Thus, if virus replication after ablation of
immune control functions reveals the real frequency of nat-
urally occurring reactivation events, the lack of infectious
virus during latency in antibody-negative mice must indi-
cate that the immunosurveillance functions extinguish re-
activation events and operate before the formation of an in-
fectious virus progeny.
Impact of T Cell Subsets and NK Cells on Recurrent CMV
Infection. To characterize the phenotype of cells involved
in immune control and their relative contribution, latently
infected mice were depleted of T lymphocyte subsets by
injections of cytolytic anti-CD4 and/or anti-CD8 mAbs.
2 wk after the initiation of antibody treatment, the pres-
ence of infectious virus was quantitated in the salivary
glands, the spleen, and the lungs by virus titration. The
ability to detect infectious virus, irrespective of the titer, in
any of the organs was scored as recurrent infection. Only
rarely did the removal of a single T cell subset result in pro-
ductive reactivation in an animal (Fig. 2 A). In contrast, 15
out of 21 animals (73%) were scored positive after deple-
tion of both CD41 and CD81 T cells (Fig. 2 A), and virus
became detectable in the salivary glands and lungs. How-
ever, this immunosuppression protocol did not lift the im-
mune control in the spleen (Fig. 2 B). In conclusion, nei-
ther the CD41 nor the CD81 subset was indispensable for
the maintenance of latency, indicating a mutual functional
redundancy of both T cell subsets. In addition, in the ab-
sence of both CD81 and CD41 T cells, MCMV recur-
rence is still prevented in the splenic tissue.
The absence of recurrent virus in the spleen of T cell–
depleted animals suggested a pivotal role for NK cells in the
Table 1. Detection of Recurrent MCMV in Organs of Individual 
Mice 14 d after Depletion of CD41, CD81, and NK1.11 Cells
Mouse Salivary glands Lungs Spleen
1 33 133 67
2 1200 4600 124
3 1000 4600 67
4 1300 15000 200
5 4000 4000 67
6 24600 24000 78
7 157000 4000 120
8 22 10 0
9 24000 500 120
10 90660 400 6
11 2000 86 68
12 250000 2000 0
Table 2. MCMV Recurrence in Mice after Combined Depletion of 
NK Cells and T Lymphocyte Subsets
mAb treatment
No. of mice with recurrent
infection (%)
Salivary glands Lungs Spleen
aNK 1/18 (5.6) 0/18 (0) 0/18 (0)
aCD4 1 aNK 6/24 (25) 1/24 (4.2) 0/24 (0)
aCD8 1 aNK 12/15 (80) 13/15 (86.7) 12/15 (80)
aCD4 1 aCD8 1 aNK 25/25 (100) 25/25 (100) 22/25 (88)
Latently infected B cell–deficient mice (mMT/mMT) were depleted of
NK cells, either alone or in combination with CD41 and/or CD81 T
lymphocytes. 2 wk later, organs were analyzed for recurrent MCMV.
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control of persistent CMV infection in the spleen. There-
fore, the contribution of NK cells was tested (Table 2). The
selective removal of NK cells was not sufficient to allow re-
current infection in any of the organs investigated, includ-
ing the spleen (Table 2). To determine the potential coop-
eration between NK and T cells, latently infected mice
were depleted of NK cells simultaneously with either
CD41 or CD81, or both T cell subsets. Depletion of
CD41 and NK cells permitted recurrent infection in only
25% of the animals, and recurrent virus was detected
mainly in the salivary glands, but not in the spleen. In con-
trast, depletion of both CD81 and NK cells allowed the
detection of virus in 100% of the animals in one of the or-
gans tested, although not in every analyzed organ of each
individual animal.
To assess the regulating function of CD41 T lympho-
cytes in the control of recurrent CMV infection, virus pro-
ductivity was compared in mice depleted of CD81 T lym-
phocytes and NK cells in the presence and absence of
CD41 T cells (Table 2). Under these conditions, CD41 T
cells restricted virus replication in the salivary glands and
lungs to titers 1–2 log10 PFU lower (data not shown). From
the collective data, we conclude that (a) the removal of one
lymphocyte subset alone, irrespective of CD41, CD81, or
NK cells, is insufficient to allow MCMV recurrence; (b) in
the absence of NK cells, the CD81 subset is much more ef-
fective in virus control compared with CD41; (c) control of
recurrence is lifted in the absence of CD81 and NK cells,
although CD41 T cells can limit the extent of multiplica-
tion of recurrent virus in this situation. Altogether, the pre-
vention and control of recurrent CMV infection are se-
cured by multiple, hierarchic, and functionally redundant
lymphocyte populations.
IFN-g Participates in the Control of CMV Recurrence.
Previous studies demonstrated that IFN-g is essential for
the termination of primary CMV infection in vivo (17) and
combats the cytomegaloviral escape from antigen presenta-
tion to CD81 T cells (18). To assess the role of IFN-g in
the prevention of virus recurrence, latently infected B cell–
deficient mice were depleted of IFN-g by neutralizing
mAb with or without simultaneous depletion of either
CD41 or CD81 T lymphocytes. As depicted in Table 3,
CMV recurrence was detected only rarely in mice selec-
tively ablated of only CD41 or CD81 T lymphocytes.
Likewise, selective neutralization of IFN-g did not induce
recurrent infection in latently infected B cell–deficient
mice. Strikingly, single T cell subset depletion of either
CD41 or CD81 T cells together with IFN-g neutralization
yielded recurrent infection in z75% of mice.
Next, we tested whether in this situation application of
rIFN-g is able to maintain the nonproductive state of in-
fection in T and NK cell–depleted animals when adminis-
tered in a dose sufficient to exert systemic antiviral effects
in vivo (references 17 and 19, and data not shown). We
constantly failed to achieve this goal, and concluded that
systemic IFN-g therapy is not sufficient to prevent local re-
current CMV infection, but IFN-g is essential to ascertain
the functional redundancy of latency control by CD41 and
CD81 T cells.
Discussion
In this study, we took advantage of the 100–1,000-fold
facilitated detectability of recurrent MCMV in B cell–defi-
cient mice and an optimized isolation of infectious virus in
vitro. This combined approach provided for the first time
the opportunity to assess the individual roles of CD81and
CD41 T cells, NK cells, and IFN-g in the control of recur-
Figure 2. Recurrent infection after selec-
tive depletion of T cell subsets. (A) Latently
infected B cell–deficient mice were de-
pleted of CD41 and/or CD81 T lympho-
cytes. Virus titration of the spleen, lungs,
and salivary glands was performed 2 wk
later. Shown are percentages of mice with
infectious virus in at least one of the organs
analyzed. (B) Recurrent virus in mice de-
pleted of CD41 and CD81 T cells. Titers of
individual mice (d) and median values (hor-
izontal lines) are shown. Dashed line, Detec-
tion limit of infectious virus.
Table 3. Participation of IFN-g in T Cell–mediated Control of 
Recurrent MCMV Infection
mAb treatment No. of mice with recurrent infection (%)
Control 0/20 (0)
aIFN-g 0/15 (0)
aCD4 2/17 (11.8)
aCD4 1 aIFN-g 10/13 (76.9)
aCD8 1/23 (4.3)
aCD8 1 aIFN-g 11/15 (73.3)
Latently infected B cell–deficient mice (mMT/mMT) were depleted of
IFN-g either alone or in combination with CD41 and/or CD81 T
lymphocytes. 2 wk later, salivary glands, lungs, and spleen were tested
for recurrent MCMV. Mice showing recurrent virus in any of these or-
gans were scored positive.
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rent CMV infection. The stepwise withdrawal of immune
control functions revealed that both the CD81 and CD41
T cell subsets as well as NK cells contribute to CMV con-
trol in a hierarchic but not exclusive fashion. The data doc-
ument a previously undescribed propensity of CMV to fre-
quently initiate productive replication cycles which, in the
absence of cellular immune control, result in virus recur-
rence.
This new finding suggests that the maintenance of sys-
temic CMV latency is less determined by specific factors of
the cell in which CMV is latent, than primarily governed
by immune functions mediated by T lymphocytes and NK
cells. This situation is remarkable because it differs from the
concepts of herpesviral latency that have been established
for human alpha- and gammaherpesviruses, i.e., herpes
simplex virus (HSV) and EBV, respectively. In contrast to
CMV, the cellular compartment of viral persistence is de-
fined for both HSV and EBV (20, 21). HSV establishes la-
tency in neurons that represent a site of exceptional immu-
noprivilege, e.g., devoid of MHC molecules and therefore
barely controlled by T cells (22, 23). Rather, nonimmune
stimuli such as physical or emotional stress, intake of hor-
mones, or administration of drugs can induce HSV recur-
rence (20). Only the release of virus progeny after retro-
grade axonal transport exposes HSV to the host immune
response, which restricts the recurrent infection to local
mucosal tissues. Likewise, nonproductive EBV carriage in
B lymphocytes is interpreted as a state of immunological si-
lence. Remarkably, EBV can restrict viral gene expression,
and a subpopulation of infected B cells expressing only
EBNA1 has been found in seropositive individuals (24). In
the light of a minimal or even absent antigenicity of
EBNA1 (25), it is plausible to assume that this B cell com-
partment represents the reservoir where EBV can persist
without detection by T cells. CMV, too, expresses genes
that avoid the detection of infected cells by T cells at least
during productive infection (for a review, see reference 7).
It will be interesting to learn whether CMV like EBV use
these functions to modulate the host immune response
during latency.
Memory T cells have been thought to be dormant and
inactive in the absence of their specific antigen. However,
recent work has shown that memory CD81 T cells are rap-
idly able to resume effector functions like secretion of IFN-g
or cytolytic activity within a few hours of antigen contact
without the need to divide and differentiate (26, 27). Our
finding that latent CMV infection immediately returns to
productive virus replication after withdrawal of T and/or
NK cells suggests that the nonproductive state of CMV la-
tency represents in fact a state of active cellular immune
control. How could these immune cells prevent reactiva-
tion of productive infection? MCMV and in particular
HCMV are very slowly replicating viruses. Both NK cells
and CD81 lymphocytes are cytolytic effector cells which
are able to recognize and lyse infected target cells before
the formation of infectious virus. In addition, T and NK
cells release specific cytokines, i.e., IFN-g and TNF-a,
which can efficiently inhibit late gene transcription and
block CMV replication at the stage of nucleocapsid forma-
tion (28). Accordingly, the neutralization of IFN-g gives
rise immediately to recurrent infection when combined
with the depletion of either CD81 or CD41 T lympho-
cytes. The idea that CMV latency is controlled by immu-
nological forces is further supported by the demonstration
of viral gene expression in tissues harboring latent CMV
genomes (29–32). Viral gene expression during latency
provides a source of viral antigen for continuous immuno-
logical restimulation which is enhanced by IFN-g (18, 19).
The presented antigens could activate CMV-specific T
cells and constantly drive the emigration of recirculating
lymphocytes into latently infected solid tissues (33).
In the past, experimental analysis of immune responses
against CMV has focused on studying the primary infection
in the immunologically naive host (11, 14, 34–39). How-
ever, in the natural situation, CMV persists lifelong in its
host, with phases of latent or nonproductive and recurrent
or productive infection which expose the virus to the most
part to an already primed immune system. In this context,
two principal aspects require attention: first, whether there
are differences in the immune response to recurrent versus
primary CMV infection, and second, whether virus pro-
ductivity in tissues is altered in recurrent infections com-
pared with primary infection.
In primary infected BALB/c mice, CD81 T cells play a
major and protective role by clearing productive infection
in visceral organs, with the exception of the epithelial cells
of the salivary glands (10, 14). Resolution of acute MCMV
infection in this particular tissue is mediated primarily by
CD41 T cells (11). NK cells delay but fail to protect from
lethal disease (37), while antibodies are dispensable for the
resolution of primary infection (8). Unlike BALB/c mice,
selective depletion of CD81 T cells has little effect on virus
clearance during the course of primary infection in C57/
BL6 mice (38). Here, NK cells prominently contribute to
the suppression of virus replication during primary infec-
tion due to the Cmv-1 gene locus, which confers NK cell–
dependent resistance to MCMV to this strain of mice (39).
Remarkably, for the control of recurrent infection in C57/
BL6 mice, not NK cells but CD81 T cells exhibit the most
prominent function.
There are also differences in the sequence of organs pro-
ducing CMV during recurrence. In the naive host, CMV
replicates first in visceral organs, including the lungs,
spleen, and liver. In a later phase of infection, when virus
multiplication in these tissues is already ceasing due to
clearance of infectious virus by CD81-dependent immune
control functions, increasing titers are found in the salivary
glands. There, infectious virus persists for .2 mo to be
cleared by CD41-mediated functions (14, 17). Frequently,
the sequence of recurrent infection is the reverse of the pri-
mary infection: reactivated virus emerged first in the sali-
vary glands. Notably, and unlike the clearance of primary
infection, the ablation of CD81 T cells is more crucial for
reactivation than the depletion of CD41 T cells (see Table
2). Next, recurrent infections occurred in the lungs and fi-
nally in the spleen, revealing an organ-specific control of
1053 Poli  et al.c´
recurrence of different stringency. Thus, our findings re-
produce clinical experience, in that asymptomatic recurrent
infection has to be distinguished from recurrent disease. Al-
though the former is usually associated with virus shedding
at focal sites, e.g., into the saliva or urine, the latter is man-
ifested by disseminated infection in visceral organs (3). Fi-
nally, our results define the salivary glands as a site of partic-
ular risk of recurrence compared with other tissues. A
preferential but restricted recurrence at this site favors virus
shedding and transmission without harming the host. This
observation cannot be explained by the tissue load of latent
CMV, because the burden of latent CMV genomes is not
higher in the salivary glands (5).
In essence, the data show that recurrent CMV infection
is not a repetition of the primary infection. The incidence
and kinetics of recurrence are tightly regulated by distinct
cellular immune functions which operate in a redundant
fashion and in a hierarchical order. With the advent of a
growing number of drugs designed for selective immune
suppression, a better understanding of the key immune
functions in CMV immune surveillance offers a rational ba-
sis for prevention of disease manifestations in patients at
risk. The B cell–deficient mouse may provide a promising
model that allows mimicking of the manifestations of re-
current human CMV disease, e.g., retinitis or interstitial
pneumonia, that are not yet fully understood.
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